- Published on
Emergency and Acute Medicine – Pelvic Inflammatory Disease
Pelvic inflammatory disease (PID) is an acute, community-acquired, sexually transmitted infection involving the upper female genital tract, including the uterus, fallopian tubes, ovaries, and adjacent pelvic structures. It is one of the most common gynecologic reasons for emergency department visits, accounting for hundreds of thousands of cases annually. PID represents a spectrum of disease rather than a single entity, and there is no definitive diagnostic gold standard. Because delayed treatment increases the risk of infertility, chronic pelvic pain, and ectopic pregnancy, clinicians must maintain a low threshold for diagnosis and initiate empiric antibiotic therapy when PID is suspected. Progressive or untreated infection may result in complications such as tubo-ovarian abscess (TOA). An important associated condition is Fitz-Hugh–Curtis syndrome, a perihepatic capsular inflammation that presents with sharp right upper quadrant pain worsened by movement, coughing, or inspiration.
The most important risk factors for PID include age younger than 25 years, multiple or symptomatic sexual partners, a prior history of PID, nonbarrier contraception, and certain demographic factors such as African American ethnicity. The most common causative organisms are *Chlamydia trachomatis* and *Neisseria gonorrhoeae*, although PID is frequently polymicrobial. Other implicated pathogens include group A and B streptococci, staphylococci, gram-negative rods such as *Escherichia coli*, *Klebsiella* spp., *Proteus* spp., and various anaerobes. Because of this broad microbiologic spectrum, treatment regimens must provide wide antimicrobial coverage.
Clinically, PID most often presents with bilateral lower abdominal or pelvic pain, which may range from mild and subtle to severe. Pain that worsens during intercourse or occurs shortly after or during menses is particularly suggestive. Associated symptoms commonly include abnormal vaginal discharge, abnormal uterine bleeding, dysmenorrhea, dyspareunia, dysuria, nausea, vomiting, fever, and chills. On examination, only about half of patients are febrile. Abdominal examination typically reveals lower quadrant tenderness, often bilateral, with possible rebound tenderness and decreased bowel sounds. Pelvic examination may demonstrate purulent endocervical discharge, cervical motion tenderness, and uterine or adnexal tenderness. Right upper quadrant tenderness in the context of PID suggests Fitz-Hugh–Curtis syndrome. Importantly, the absence of prominent uterine or adnexal tenderness should prompt consideration of alternative diagnoses.
The diagnosis of PID is primarily clinical and based on history and physical examination, including a pelvic exam. A pregnancy test is mandatory in all patients to exclude ectopic pregnancy or complications of intrauterine pregnancy. Minimum diagnostic criteria include the presence of lower abdominal tenderness, uterine or adnexal tenderness, or cervical motion tenderness. Supportive findings include fever above 38.3°C, abnormal cervical or vaginal discharge, leukocytosis, elevated inflammatory markers such as ESR or C-reactive protein, and microbiologic evidence of gonococcal or chlamydial infection. Laboratory studies may include a complete blood count, nucleic acid amplification testing for *N. gonorrhoeae* and *C. trachomatis*, and microscopic evaluation of vaginal discharge. Imaging is not routinely required but transvaginal ultrasound is indicated when adnexal fullness or mass is present, when TOA is suspected, when pelvic examination is limited, or when outpatient therapy fails.
Management depends on disease severity and patient reliability for follow-up. Most patients with mild to moderate PID can be treated as outpatients with intramuscular ceftriaxone or cefoxitin (with probenecid) plus oral doxycycline, with the addition of metronidazole when anaerobic coverage is indicated. Inpatient therapy is reserved for patients with severe illness, pregnancy, suspected TOA, immunodeficiency, inability to tolerate oral medications, failure of outpatient therapy, or concern for noncompliance. Recommended inpatient regimens include doxycycline combined with cefoxitin or cefotetan, or alternatives such as gentamicin plus clindamycin or ampicillin/sulbactam plus doxycycline. Parenteral therapy should continue for at least 24 hours after clinical improvement, followed by oral antibiotics to complete a 14-day course. Sexual partners should be evaluated and treated, and patients should receive counseling and testing for other sexually transmitted infections, including HIV.
Patients who do not meet admission criteria may be safely discharged with close follow-up arranged within 48–72 hours to ensure clinical improvement. Failure to improve within this timeframe warrants reassessment and possible inpatient management. Key clinical principles include recognizing that PID exists along a disease continuum, that early empiric treatment is essential to prevent long-term sequelae, and that quinolones and oral cephalosporins are no longer recommended in the United States for gonorrhea-related infections due to resistance. Comprehensive patient education, partner treatment, and reliable follow-up are critical components of effective PID management.
Pelvic inflammatory disease (PID) is an acute, community-acquired, sexually transmitted infection involving the upper female genital tract, including the uterus, fallopian tubes, ovaries, and adjacent pelvic structures. It is one of the most common gynecologic reasons for emergency department visits, accounting for hundreds of thousands of cases annually. PID represents a spectrum of disease rather than a single entity, and there is no definitive diagnostic gold standard. Because delayed treatment increases the risk of infertility, chronic pelvic pain, and ectopic pregnancy, clinicians must maintain a low threshold for diagnosis and initiate empiric antibiotic therapy when PID is suspected. Progressive or untreated infection may result in complications such as tubo-ovarian abscess (TOA). An important associated condition is Fitz-Hugh–Curtis syndrome, a perihepatic capsular inflammation that presents with sharp right upper quadrant pain worsened by movement, coughing, or inspiration.
The most important risk factors for PID include age younger than 25 years, multiple or symptomatic sexual partners, a prior history of PID, nonbarrier contraception, and certain demographic factors such as African American ethnicity. The most common causative organisms are *Chlamydia trachomatis* and *Neisseria gonorrhoeae*, although PID is frequently polymicrobial. Other implicated pathogens include group A and B streptococci, staphylococci, gram-negative rods such as *Escherichia coli*, *Klebsiella* spp., *Proteus* spp., and various anaerobes. Because of this broad microbiologic spectrum, treatment regimens must provide wide antimicrobial coverage.
Clinically, PID most often presents with bilateral lower abdominal or pelvic pain, which may range from mild and subtle to severe. Pain that worsens during intercourse or occurs shortly after or during menses is particularly suggestive. Associated symptoms commonly include abnormal vaginal discharge, abnormal uterine bleeding, dysmenorrhea, dyspareunia, dysuria, nausea, vomiting, fever, and chills. On examination, only about half of patients are febrile. Abdominal examination typically reveals lower quadrant tenderness, often bilateral, with possible rebound tenderness and decreased bowel sounds. Pelvic examination may demonstrate purulent endocervical discharge, cervical motion tenderness, and uterine or adnexal tenderness. Right upper quadrant tenderness in the context of PID suggests Fitz-Hugh–Curtis syndrome. Importantly, the absence of prominent uterine or adnexal tenderness should prompt consideration of alternative diagnoses.
The diagnosis of PID is primarily clinical and based on history and physical examination, including a pelvic exam. A pregnancy test is mandatory in all patients to exclude ectopic pregnancy or complications of intrauterine pregnancy. Minimum diagnostic criteria include the presence of lower abdominal tenderness, uterine or adnexal tenderness, or cervical motion tenderness. Supportive findings include fever above 38.3°C, abnormal cervical or vaginal discharge, leukocytosis, elevated inflammatory markers such as ESR or C-reactive protein, and microbiologic evidence of gonococcal or chlamydial infection. Laboratory studies may include a complete blood count, nucleic acid amplification testing for *N. gonorrhoeae* and *C. trachomatis*, and microscopic evaluation of vaginal discharge. Imaging is not routinely required but transvaginal ultrasound is indicated when adnexal fullness or mass is present, when TOA is suspected, when pelvic examination is limited, or when outpatient therapy fails.
Management depends on disease severity and patient reliability for follow-up. Most patients with mild to moderate PID can be treated as outpatients with intramuscular ceftriaxone or cefoxitin (with probenecid) plus oral doxycycline, with the addition of metronidazole when anaerobic coverage is indicated. Inpatient therapy is reserved for patients with severe illness, pregnancy, suspected TOA, immunodeficiency, inability to tolerate oral medications, failure of outpatient therapy, or concern for noncompliance. Recommended inpatient regimens include doxycycline combined with cefoxitin or cefotetan, or alternatives such as gentamicin plus clindamycin or ampicillin/sulbactam plus doxycycline. Parenteral therapy should continue for at least 24 hours after clinical improvement, followed by oral antibiotics to complete a 14-day course. Sexual partners should be evaluated and treated, and patients should receive counseling and testing for other sexually transmitted infections, including HIV.
Patients who do not meet admission criteria may be safely discharged with close follow-up arranged within 48–72 hours to ensure clinical improvement. Failure to improve within this timeframe warrants reassessment and possible inpatient management. Key clinical principles include recognizing that PID exists along a disease continuum, that early empiric treatment is essential to prevent long-term sequelae, and that quinolones and oral cephalosporins are no longer recommended in the United States for gonorrhea-related infections due to resistance. Comprehensive patient education, partner treatment, and reliable follow-up are critical components of effective PID management.
0 Comments
